Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
about
Ontogeny of early life immunityEvaluation of swabbing methods for estimating the prevalence of bacterial carriage in the upper respiratory tract: a cross sectional studyThe response to Typhi Vi vaccination is compromised in individuals with primary immunodeficiency.Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.Invasive pneumococcal infections in Vellore, India: clinical characteristics and distribution of serotypes.Optimal serotype compositions for Pneumococcal conjugate vaccination under serotype replacement.Emerging, Non-PCV13 Serotypes 11A and 35B of Streptococcus pneumoniae Show High Potential for Biofilm Formation In Vitro.Towards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.Structural characterization of Streptococcus pneumoniae serotype 9A capsule polysaccharide reveals role of glycosyl 6-O-acetyltransferase wcjE in serotype 9V capsule biosynthesis and immunogenicity.Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.Next generation protein based Streptococcus pneumoniae vaccinesInvasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccineTLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.The fundamental link between pneumococcal carriage and disease.The history of pneumococcal conjugate vaccine development: dose selection.Glycoconjugate vaccines: an update.Invasive pneumococcal disease in patients with haematological malignancies before routine use of conjugate vaccines in Finland.Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens.Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.Position of O-Acetylation within the Capsular Repeat Unit Impacts the Biological Properties of Pneumococcal Serotypes 33A and 33F.Pneumococcal Vaccines - How Many Serotypes are Enough?Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.
P2860
Q27000632-74CD06EA-63B7-4595-92C1-CD0E46FA82D6Q28652846-049A6F21-6E1B-4D35-B6C1-07D4587FDD6EQ33840276-BE9A79AC-3234-440C-81AD-90974DBC0DF4Q34291155-8C1BD426-630A-48C7-80C1-B1A7EA370F29Q35037317-17F62897-DABB-4931-AF1C-927091EA520FQ35097094-8838AE20-D371-40F2-8970-053B073E6C74Q35619025-6AFBC78E-9DA2-4B40-B8B4-5A3D3D7B8446Q35826592-240533BF-65CC-41DA-9CB2-536B6859289AQ35922324-8B0D4122-E19B-4C0E-879D-C1C42040DD52Q36017771-EF96ADF2-D6E0-4B8B-80AF-5D3D7E1F2F5EQ36156085-9EA02E0D-8463-4207-AEBC-CDE5CA87873BQ37130191-8453A711-EE28-48E5-9BA3-0652A186DE84Q37335485-46A1D784-6517-4EDB-9C90-F788EFB9EC11Q37713832-582FEC5A-C54E-404C-9145-A84264C87B5CQ38036689-81323437-2717-4807-9E46-62E4051F0019Q38160248-360ADE35-B0F5-4268-A074-31FC9888DA7EQ38286346-7BCDAC8F-EEA1-4CF5-A839-3DB18546610AQ38935505-33E4A861-879D-4DC7-8A81-A422470E1D74Q40070485-47022202-5400-4C7E-A84C-C4F318EE6EE2Q41437357-E0E1AAEA-2C45-4819-9C43-5240456DBE61Q44398866-6551381A-94D6-440E-A1E8-FAD36E2A7F86Q49215526-9B0303A8-6000-4D41-A61A-6F155C5599B7Q50192579-ACC92C3D-077F-466E-9451-0961F1E6222FQ55310096-159DA68E-FD29-4C44-8A7D-994A853FA8E2
P2860
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Pre-clinical evaluation of a 1 ...... s monkey immunogenicity model.
@en
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine
@nl
type
label
Pre-clinical evaluation of a 1 ...... s monkey immunogenicity model.
@en
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine
@nl
prefLabel
Pre-clinical evaluation of a 1 ...... s monkey immunogenicity model.
@en
Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine
@nl
P2093
P1433
P1476
Pre-clinical evaluation of a 1 ...... s monkey immunogenicity model.
@en
P2093
Jayme Cannon
Jeffrey Blue
John Macnair
John Shiver
Jon H Heinrichs
Joseph Antonello
Julie M Skinner
Lani Indrawati
Michael Caulfield
Michael Winters
P304
P356
10.1016/J.VACCINE.2011.09.078
P407
P577
2011-10-01T00:00:00Z